Core B serves the MSCP SPORE as the Biospecimen Core, as well as the Immunologic Monitoring and Cellular Products Laboratory (IMCPL). The laboratory supports the SPORE community with blood and tissue banking for patients submitting blood and/or tumor to the Melanoma Program tissue bank (#96-099), as well as ciinicai protocol-specific banking. For all of the projects proposed in this renewal, the Core wiil perform a wide variety of standardized, SOP-driven immunological monitoring assays. For Project 2, Core B will also prepare autologous dendritic cell vaccines. Core B will support each Project as follows: Project 1 (Tarhini/Storkus) Core B will support Project 1 Aims 1a and lb, testing circulating cellular and serum biomarkers from the trial ECOG 1609. Core B will assess host effector and suppressor cellular immune responses. We will perform multicolor flow cytometry to compare PBMC before and after treatment, focusing on circulating suppressor cells (Treg and MDSC) and antigen-specific effector and helper T cells, as well as serum biomarkers. Project 2 (Butterfield/Kirkwood): The Core will support Aim 1 (clinical trial #09-021) with autologous AdVTMM2-transduced dendritic cell vaccine manufacture, characterization and release for therapy. The Core will process all blood, leukapheresis and tumor samples and perform all banking For Aim 2, The Core will perform many standardized immune response assays. Project 3 (Zarour/Ferrone): The Core will support this Project with banking of PBMC and testing for activation and expansion of shared melanoma antigen-specific T cells. Project 4 (Falo/Geskin/Tawbi) Core B will perform the systemic immunologic monitoring proposed in Project 4 for both CTCL and melanoma patients. This will include serum, PBMC and tumor sample banking and testing, including innate and effector cell analysis. Together, the Biospecimen Core B will support the projects of the SPORE with tissue banking (all Projects), standardized immunologic monitoring (all Projects) and cGMP cellular product production for therapy (Project 2). Data generated in Core B will be analyzed in Biostatistics Core C and correlated to clinical parameters. The blood and tissue bank data and inventory are linked to the Clinical Trials Management Application and and will be part of the Research Data Warehouse developed by and managed in Informatics Core D.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-07
Application #
8933151
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Agarwal, Rajeev K
Project Start
2006-07-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$404,952
Indirect Cost
$142,435
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Mathers, A R; Carey, C D; Killeen, M E et al. (2017) Electrophilic nitro-fatty acids suppress allergic contact dermatitis in mice. Allergy 72:656-664
Davar, Diwakar; Ding, Fei; Saul, Melissa et al. (2017) High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer 5:74
Booth, Laurence; Roberts, Jane L; Sander, Cindy et al. (2017) The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget 8:16367-16386
Najjar, Yana G; Ding, Fei; Lin, Yan et al. (2017) Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. J Transl Med 15:39
Butterfield, Lisa H (2017) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol :
Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2017) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol :
Ferris, Laura K; Saul, Melissa I; Lin, Yan et al. (2017) A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol 3:1112-1115
Scharping, Nicole E; Menk, Ashley V; Whetstone, Ryan D et al. (2017) Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol Res 5:9-16
Overacre-Delgoffe, Abigail E; Chikina, Maria; Dadey, Rebekah E et al. (2017) Interferon-? Drives Treg Fragility to Promote Anti-tumor Immunity. Cell 169:1130-1141.e11
Kalinsky, Kevin; Lee, Sandra; Rubin, Krista M et al. (2017) A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 123:2688-2697

Showing the most recent 10 out of 191 publications